(Q37977556)

26 August 2017

Hereditary ovarian cancer: beyond the usual suspects (English)

1 reference

26 August 2017

1 reference

Kathryn P Pennington

1

1 reference

PubMed ID

22264603

26 August 2017

Elizabeth M Swisher

series ordinal

2

1 reference

PubMed ID

22264603

26 August 2017

language of work or name

English

0 references

publication date

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

124

1 reference

26 August 2017

2

1 reference

26 August 2017

347-353

1 reference

Germline mutations in RAD51D confer susceptibility to ovarian cancer

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Mutations in BRIP1 confer high risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Susceptibility pathways in Fanconi's anemia and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Pathology of ovarian cancers in BRCA1 and BRCA2 carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Cancer risk associated with germline DNA mismatch repair gene mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Fanconi anemia and its diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Molecular pathogenesis of Fanconi anemia: recent progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

The genetic and molecular basis of Fanconi anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Mutations of the SLX4 gene in Fanconi anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Biallelic inactivation of BRCA2 in Fanconi anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Cancer predisposition of ataxia-telangiectasia heterozygotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

A novel germline PALB2 deletion in Polish breast and ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Mutation of the RAD51C gene in a Fanconi anemia-like disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Common variants at 19p13 are associated with susceptibility to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Common genetic variation and human traits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Genetic heterogeneity in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Advances in understanding cancer genomes through second-generation sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

A polymorphic stop codon in BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.12.415

10.1016/J.YGYNO.2011.12.415

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22264603